“There is no admission of liability, and we remain steadfast that the claims raised in the litigation contradict years of scientific data and the U.S. Food and Drug Administration’s repeated confirmation of Xarelto’s safety and efficacy.” These are the words a Janssen Pharmaceuticals spokeswoman emailed the Associated Press in an effort to take the sting out of the fact that the company, along with Bayer, had just read more.... -->
continue reading...
Coumadin Use in Nursing Homes Under Scrutiny
Posted August 9, 2015 in Product News and Recalls
Coumadin has been a staple of the medical community for decades. As one of the most popular blood thinners on the market, the drug has been used by millions of patients. Doctors are learning, however, that no two patients react to the drug the same way. In fact, it may be (as one doctor put it) “the most dangerous drug in America.”
Nowhere is this becoming more evident than in ...
continue reading...Study: Risky Pradaxa blood clot treatment may be unnecessary
Posted June 4, 2012 in Health | Pradaxa Internal Bleeding | Product Liability | Product News and Recalls
A randomized, double-blind clinical trial indicates that aspirin works just as well as the commonly prescribed blood thinner warfarin in preventing blood clots.
According to a report in the New York Times, this is significant because aspirin is easier to take. Warfarin requires a monthly blood test, and also restricts activities for patients because of its tendency to cause bleeding.
The anti-coagulant Pradaxa was ostensibly designed to replace warfarin, based on manufacturer ...
continue reading...Pradaxa more dangerous than alternative
Posted May 22, 2012 in Health | Pradaxa Internal Bleeding | Product Liability | Product News and Recalls
A study recently presented to the 2012 Thombosis and Hemostasis Summit of North America compared Pradaxa to Coumadin and found that Pradaxa has a higher risk of bleeding and other complications.
Manufacturer Boehringer Ingelheim Pharma markets Pradaxa as a preferable alternative to warfarin, because Pradaxa, despite these risks, doesn’t require frequent blood tests.
The two blood thinners are known by their chemical names warfarin, sold under brand name Coumadin, and dabigatran, ...
continue reading...
An article in the spring issue of “The Safety Report” gives an account of a woman who died of gastrointestinal hemorrhage after switching to the anti-coagulant Pradaxa.
According to the account, she’d been taking anti-coagulant Coumadin for years because of a heart rhythm problem known as atrial fibrillation. Pradaxa was marketed as a therapeutic simplification that, unlike Coumadin, doesn’t require patients to get monthly blood tests.
Boehringer Ingelheim, the manufacturers of ...
continue reading...
